Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial
Tarih
2003Yazar
Overgaard, J
Abeyakoon, S
Hadjieva, T
Turkan, S
Tatsuzaki, H
Dinshaw, KA
Wahid, I
Grau, C
Agarwal, JP
Jabeen, K
Khan, AR
Üst veri
Tüm öğe kaydını gösterÖzet
Background and purpose: Single agent mitomycin c (MMC) has been shown to improve the outcome of radiotherapy in single institution trials. In order to confirm these findings in a broader worldwide setting, the International Atomic Energy Agency (IAEA) initiated a multicentre trial randomising between radiotherapy alone versus radiotherapy plus MMC.
Koleksiyonlar
- Makale [92796]